{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:00:56Z","timestamp":1766073656849,"version":"3.48.0"},"reference-count":47,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-0481_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Our study sought to determine the usefulness of biomarkers of systemic inflammation (C-reactive protein (CRP), procalcitonin (PCT) and proadrenomedullin (proADM)) on hospital admission, as compared to the CURB65 score, for predicting 30- and 90-day mortality in patients hospitalized for community acquired pneumonia (CAP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0481_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Observational, prospective study of adults admitted for CAP in four Spanish teaching hospitals. Disease severity was determined within the first 24\u202fh of diagnosis, using the CURB65 score. CRP, PCT and proADM levels were assessed from samples obtained in the Emergency Department (ED). We compared the capacity of the different biomarkers and the CURB65 score to predict pneumonia-related 30- and 90-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0481_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 956 patients hospitalized with CAP were included, 462 in the internal and 494 in the external sample. Of the biomarkers, proADM showed the greatest AUC for predicting 30- and 90-day mortality (0.80 and 0.76 respectively). Mortality at 30 and 90\u00a0days increased as proADM levels rose. When proADM was used as a continuous variable, CURB65 showed a similar predictive capacity (AUC 0.80) to both crude and age-adjusted proADM (AUC 0.80 and 0.83 respectively) for 30-day mortality. The same was also true for 90-day mortality. However, proADM used as a categorical variable had a greater predictive capacity for 90-day mortality than the CURB65 score (&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0481_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Amongst patients admitted for CAP, the use of proADM obtained in the ED may be useful for identifying patients at greatest risk of mortality, with a similar predictive capacity to the CURB65\u00a0score.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-0481","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T07:31:58Z","timestamp":1758094318000},"page":"250-259","source":"Crossref","is-referenced-by-count":0,"title":["Proadrenomedullin for prediction of early and mid-term mortality in patients hospitalized for community-acquired pneumonia"],"prefix":"10.1515","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1869-9193","authenticated-orcid":false,"given":"Amaia","family":"Artaraz","sequence":"first","affiliation":[{"name":"Respiratory Department , Galdakao-Usansolo University Hospital , Galdakao , Bizkaia , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ane","family":"Uranga","sequence":"additional","affiliation":[{"name":"Respiratory Department , Galdakao-Usansolo University Hospital , Galdakao , Bizkaia , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"J\u00f3dar","sequence":"additional","affiliation":[{"name":"Respiratory Department , Galdakao-Usansolo University Hospital , Galdakao , Bizkaia , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urko","family":"Aguirre","sequence":"additional","affiliation":[{"name":"Research Unit , Galdakao-Usansolo University Hospital , Galdakao , Bizkaia , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Quintana","sequence":"additional","affiliation":[{"name":"Research Unit , Galdakao-Usansolo University Hospital , Galdakao , Bizkaia , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Mar","sequence":"additional","affiliation":[{"name":"Biochemistry and Clinical Analysis Department , Galdakao-Usansolo University Hospital , Galdakao , Bizkaia , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Men\u00e9ndez","sequence":"additional","affiliation":[{"name":"Respiratory Department , La Fe University Hospital , Valencia , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Aspa","sequence":"additional","affiliation":[{"name":"Respiratory Department , La Princesa University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Bello","sequence":"additional","affiliation":[{"name":"Respiratory Department , Miguel Servet University Hospital , Zaragoza , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Pablo","family":"Espa\u00f1a","sequence":"additional","affiliation":[{"name":"Respiratory Department , Galdakao-Usansolo University Hospital , Galdakao , Bizkaia , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aitor","family":"Ballaz","sequence":"additional","affiliation":[{"name":"Respiratory Department , Galdakao-Usansolo University Hospital , Galdakao , Bizkaia , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"2025121815555026261_j_cclm-2025-0481_ref_001","unstructured":"Kochanek, KD, Xu, J, Murphy, SL, Mini\u00f1o, AM, Kung, HC. National vital statistics reports 2012;60:1\u2013115. Available from: https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr60\/nvsr60_03.pdf."},{"key":"2025121815555026261_j_cclm-2025-0481_ref_002","doi-asserted-by":"crossref","unstructured":"Almirall, J, Bolibar, I, Vidal, J, Sauca, G, Coll, P, Niklasson, B, et al.. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000;15:757\u201363. https:\/\/doi.org\/10.1034\/j.1399-3003.2000.15d21.x.","DOI":"10.1034\/j.1399-3003.2000.15d21.x"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_003","unstructured":"Feagan, BG, Marrie, TJ, Lau, CY, Wheeler, SL, Wong, CJ, Vandervoort, MK. Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. CMAJ 2000;162:1415\u201320."},{"key":"2025121815555026261_j_cclm-2025-0481_ref_004","doi-asserted-by":"crossref","unstructured":"Guest, JF, Morris, A. Community-acquired pneumonia: the annual cost to the national health service in the UK. Eur Respir J 1997;10:1530\u20134. https:\/\/doi.org\/10.1183\/09031936.97.10071530.","DOI":"10.1183\/09031936.97.10071530"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_005","doi-asserted-by":"crossref","unstructured":"Fine, MJ, Stone, RA, Singer, DE, Coley, CM, Marrie, TJ, Lave, JR, et al.. Processes and outcomes of care for patients with community-acquired pneumonia. Arch Intern Med 1999;159:970. https:\/\/doi.org\/10.1001\/archinte.159.9.970.","DOI":"10.1001\/archinte.159.9.970"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_006","doi-asserted-by":"crossref","unstructured":"Fine, MJ, Auble, TE, Yealy, DM, Hanusa, BH, Weissfeld, LA, Singer, DE, et al.. A prediction rule to identify low-risk patients with community-acquired pneumonia. N\u00a0Engl J Med 1997;336:243\u201350. https:\/\/doi.org\/10.1056\/nejm199701233360402.","DOI":"10.1056\/NEJM199701233360402"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_007","doi-asserted-by":"crossref","unstructured":"Men\u00e9ndez, R, Cilloniz, C, Espa\u00f1a, PP, Almirall, J, Uranga, A, M\u00e9ndez, R, et al.. Neumon\u00eda Adquirida en la Comunidad. Normativa de la sociedad espa\u00f1ola de neumolog\u00eda Y Cirug\u00eda Tor\u00e1cica (Separ). actualizaci\u00f3n 2020. Arch Bronconeumol 2020;56:1\u201310.","DOI":"10.1016\/j.arbres.2020.01.014"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_008","doi-asserted-by":"crossref","unstructured":"Men\u00e9ndez, R, Torres, A, Aspa, J, Capelastegui, A, Prat, C, Rodr\u00edguez de Castro, F. Neumon\u00eda adquirida en la comunidad. Nueva normativa de la Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR). Arch Bronconeumol 2010;46:543\u201358.","DOI":"10.1016\/j.arbres.2010.06.014"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_009","doi-asserted-by":"crossref","unstructured":"Lim, WS, van der Eerden, MM, Laing, R, Boersma, WG, Karalus, N, Town, GI, et al.. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377\u201382. https:\/\/doi.org\/10.1136\/thorax.58.5.377.","DOI":"10.1136\/thorax.58.5.377"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_010","doi-asserted-by":"crossref","unstructured":"Espa\u00f1a, PP, Capelastegui, A, Gorordo, I, Esteban, C, Oribe, M, Ortega, M, et al.. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006;174:1249\u201356. https:\/\/doi.org\/10.1164\/rccm.200602-177oc.","DOI":"10.1164\/rccm.200602-177OC"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_011","doi-asserted-by":"crossref","unstructured":"Christ-Crain, M, Opal, SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010;14:203. https:\/\/doi.org\/10.1186\/cc8155.","DOI":"10.1186\/cc8155"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_012","doi-asserted-by":"crossref","unstructured":"Brown, JS. Biomarkers and community-acquired pneumonia. Thorax 2009;64:556\u20138. https:\/\/doi.org\/10.1136\/thx.2008.110254.","DOI":"10.1136\/thx.2008.110254"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_013","doi-asserted-by":"crossref","unstructured":"Menendez, R, Martinez, R, Reyes, S, Mensa, J, Filella, X, Marcos, MA, et al.. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009;64:587\u201391. https:\/\/doi.org\/10.1136\/thx.2008.105312.","DOI":"10.1136\/thx.2008.105312"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_014","doi-asserted-by":"crossref","unstructured":"Espa\u00f1a, PP, Capelastegui, A, Mar, C, Bilbao, A, Quintana, JM, Diez, R, et al.. Performance of Pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia. J\u00a0Infect 2014;70:457\u201366. https:\/\/doi.org\/10.1016\/j.jinf.2014.12.003.","DOI":"10.1016\/j.jinf.2014.12.003"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_015","doi-asserted-by":"crossref","unstructured":"Legramante, JM, Mastropasqua, M, Susi, B, Porzio, O, Mazza, M, Miranda, AG, et al.. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores PSI and CURB. PLoS One 2017;12:e0187702. https:\/\/doi.org\/10.1371\/journal.pone.0187702.","DOI":"10.1371\/journal.pone.0187702"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_016","doi-asserted-by":"crossref","unstructured":"Bello, S, Lasierra, A, Minchol\u00e9, E, Fandos, S, Ruiz, M, Vera, E, et al.. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J 2012;39:1144\u201355. https:\/\/doi.org\/10.1183\/09031936.00080411.","DOI":"10.1183\/09031936.00080411"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_017","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger, S, Ewig, S, Giersdorf, S, Hartmann, O, Suttorp, N, Welte, T. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia. Am J Respir Crit Care Med 2010;182:1426\u201334. https:\/\/doi.org\/10.1164\/rccm.201003-0415oc.","DOI":"10.1164\/rccm.201003-0415OC"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_018","doi-asserted-by":"crossref","unstructured":"Christ-Crain, M, Morgenthaler, NG, Stolz, D, M\u00fcller, C, Bingisser, R, Harbarth, S, et al.. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006;10:R96. https:\/\/doi.org\/10.1186\/cc4955.","DOI":"10.1186\/cc4955"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_019","doi-asserted-by":"crossref","unstructured":"Schuetz, P, Wolbers, M, Christ-Crain, M, Thomann, R, Falconier, C, Widmer, I, et al.. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010;14:R106. https:\/\/doi.org\/10.1186\/cc9055.","DOI":"10.1186\/cc9055"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_020","doi-asserted-by":"crossref","unstructured":"Huang, DT, Angus, DC, Kellum, JA, Pugh, NA, Weissfeld, LA, Struck, J, et al.. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest. 200;136:823\u201331. https:\/\/doi.org\/10.1378\/chest.08-1981.","DOI":"10.1378\/chest.08-1981"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_021","doi-asserted-by":"crossref","unstructured":"Kruger, S, Ewig, S, Marre, R, Papassotiriou, J, Richter, K, von Baum, H, et al.. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008;31:349\u201355. https:\/\/doi.org\/10.1183\/09031936.00054507.","DOI":"10.1183\/09031936.00054507"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_022","doi-asserted-by":"crossref","unstructured":"Sungurlu, S, Balk, RA. The role of biomarkers in the diagnosis and management of pneumonia. Clin Chest Med 2018;39:691\u2013701. https:\/\/doi.org\/10.1016\/j.ccm.2018.07.004.","DOI":"10.1016\/j.ccm.2018.07.004"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_023","doi-asserted-by":"crossref","unstructured":"Nickler, M, Schaffner, D, Christ-Crain, M, Ottiger, M, Thomann, R, Hoess, C, et al.. Prospective evaluation of biomarkers for prediction of quality of life in community-acquired pneumonia. Clin Chem Lab Med 2016;54:1831\u201346. https:\/\/doi.org\/10.1515\/cclm-2016-0001.","DOI":"10.1515\/cclm-2016-0001"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_024","doi-asserted-by":"crossref","unstructured":"Pereira, JM, Paiva, JA, Rello, J. Severe sepsis in community-acquired pneumonia\u00a0\u2013\u00a0early recognition and treatment. Eur J Intern Med 2012;23:412\u20139. https:\/\/doi.org\/10.1016\/j.ejim.2012.04.016.","DOI":"10.1016\/j.ejim.2012.04.016"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_025","doi-asserted-by":"crossref","unstructured":"Haag, E, Gregoriano, C, Molitor, A, Kloter, M, Kutz, A, Mueller, B, et al.. Does mid-regional Pro-adrenomedullin (MR-proADM) improve the sequential organ failure assessment-score (SOFA score) for mortality-prediction in patients with acute infections? Results of a prospective observational study. Clin Chem Lab Med 2021;59:1165\u201376. https:\/\/doi.org\/10.1515\/cclm-2020-1566.","DOI":"10.1515\/cclm-2020-1566"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_026","doi-asserted-by":"crossref","unstructured":"Moore, N, Williams, R, Mori, M, Bertolusso, B, Vernet, G, Lynch, J, et al.. Mid-regional proadrenomedullin (MR-proADM), C-reactive protein (CRP) and other biomarkers in the early identification of disease progression in patients with COVID-19 in the acute NHS setting. J\u00a0Clin Pathol 2022;76:400\u20136. https:\/\/doi.org\/10.1136\/jclinpath-2021-207750.","DOI":"10.1136\/jclinpath-2021-207750"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_027","doi-asserted-by":"crossref","unstructured":"Long, B, Koyfman, A. Ready for prime time? Biomarkers in sepsis. Emerg Med Clin N Am 2017;35:109\u201322. https:\/\/doi.org\/10.1016\/j.emc.2016.09.004.","DOI":"10.1016\/j.emc.2016.09.004"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_028","doi-asserted-by":"crossref","unstructured":"Pereira, JM, Azevedo, A, Bas\u00edlio, C, Sousa-Dias, C, Mergulh\u00e3o, P, Paiva, JA. Mid-regional proadrenomedullin: an early marker of response in critically ill patients with severe community-acquired pneumonia? Rev Port Pneumol (English Edition) 2016;22:308\u201314. https:\/\/doi.org\/10.1016\/j.rppnen.2016.03.012.","DOI":"10.1016\/j.rppnen.2016.03.012"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_029","doi-asserted-by":"crossref","unstructured":"Stalenhoef, JE, van Nieuwkoop, C, Wilson, DC, van der Starre, WE, Delfos, NM, Leyten, EMS, et al.. Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary tract infection. J\u00a0Infect 2018;77:18\u201324. https:\/\/doi.org\/10.1016\/j.jinf.2018.05.007.","DOI":"10.1016\/j.jinf.2018.05.007"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_030","doi-asserted-by":"crossref","unstructured":"Barrio, I, Arostegui, I, Rodr\u00edguez-\u00c1lvarez, MX, Quintana, JM. A new approach to categorising continuous variables in prediction models: proposal and validation. Stat Methods Med Res 2017;26:2586\u2013602. https:\/\/doi.org\/10.1177\/0962280215601873.","DOI":"10.1177\/0962280215601873"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_031","doi-asserted-by":"crossref","unstructured":"Restrepo, MI, Faverio, P, Anzueto, A. Long-term prognosis in community-acquired pneumonia. Curr Opin Infect Dis 2013;26:151\u20138. https:\/\/doi.org\/10.1097\/qco.0b013e32835ebc6d.","DOI":"10.1097\/QCO.0b013e32835ebc6d"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_032","doi-asserted-by":"crossref","unstructured":"Carlos, P, Gomes, R, Coelho, J, Chaves, C, Tuna, C, Louro, M. CURB-65 and long-term mortality of community-acquired pneumonia: a retrospective study on hospitalized patients. Cureus 2023;15:e36052. https:\/\/doi.org\/10.7759\/cureus.36052.","DOI":"10.7759\/cureus.36052"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_033","doi-asserted-by":"crossref","unstructured":"Mortensen, E, Metersky, M. Long-term mortality after pneumonia. Semin Respir Crit Care Med 2012;33:319\u201324. https:\/\/doi.org\/10.1055\/s-0032-1315644.","DOI":"10.1055\/s-0032-1315644"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_034","doi-asserted-by":"crossref","unstructured":"Mortensen, EM, Kapoor, WN, Chang, CCH, Fine, MJ. Assessment of mortality after long-term follow-up of patients with community acquired pneumonia. Clin Infect Dis 2003;37:1617\u201324. https:\/\/doi.org\/10.1086\/379712.","DOI":"10.1086\/379712"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_035","doi-asserted-by":"crossref","unstructured":"Saeed, K, Wilson, DC, Bloos, F, Schuetz, P, van der Does, Y, Melander, O, et al.. The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation study. Crit Care 2019;23:40. https:\/\/doi.org\/10.1186\/s13054-019-2329-5.","DOI":"10.1186\/s13054-019-2329-5"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_036","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez, J, Wilson, DC, Clemente-Callejo, C, Rom\u00e1n, F, Bard\u00e9s-Robles, I, Jim\u00e9nez, I, et al.. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission. Crit Care 2019;23:335. https:\/\/doi.org\/10.1186\/s13054-019-2613-4.","DOI":"10.1186\/s13054-019-2613-4"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_037","doi-asserted-by":"crossref","unstructured":"Schuetz, P, Litke, A, Albrich, WC, Mueller, B. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis 2013;26:159\u201367. https:\/\/doi.org\/10.1097\/qco.0b013e32835d0bec.","DOI":"10.1097\/QCO.0b013e32835d0bec"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_038","doi-asserted-by":"crossref","unstructured":"Albrich, WC, R\u00fcegger, K, Dusemund, F, Schuetz, P, Birsen, A, Litke, A, et al.. Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial. Eur Respir J 2013;42:1064\u201375. https:\/\/doi.org\/10.1183\/09031936.00113612.","DOI":"10.1183\/09031936.00113612"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_039","doi-asserted-by":"crossref","unstructured":"Li, Q, Wang, BS, Yang, L, Peng, C, Ma, LB, Chai, C. Assessment of adrenomedullin and proadrenomedullin as predictors of mortality in septic patients: a systematic review and meta-analysis. Med Intensiva 2018;42:416\u201324. https:\/\/doi.org\/10.1016\/j.medine.2017.10.013.","DOI":"10.1016\/j.medin.2017.10.013"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_040","doi-asserted-by":"crossref","unstructured":"Lo, SB, Gambino, CM, Scichilone, N, Giglio, RV, Bivona, G, Scazzone, C, et al.. Clinical utility of midregional proadrenomedullin in patients with COVID-19. Lab Med 2021;52:493\u20138. https:\/\/doi.org\/10.1093\/labmed\/lmab032.","DOI":"10.1093\/labmed\/lmab032"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_041","doi-asserted-by":"crossref","unstructured":"Sozio, E, Tascini, C, Fabris, M, D\u2019Aurizio, F, De Carlo, C, Graziano, E, et al.. MR-proADM as prognostic factor of outcome in COVID-19 patients. Sci Rep 2021;11:5121. https:\/\/doi.org\/10.1038\/s41598-021-84478-1.","DOI":"10.1038\/s41598-021-84478-1"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_042","doi-asserted-by":"crossref","unstructured":"Minieri, M, Di, VN, Lia, MS, Maurici, M, Leonardis, F, Longo, S, et al.. Predictive value of MR-proADM in the risk stratification and in the adequate care setting of COVID-19 patients assessed at the triage of the emergency department. Diagnostics 2022;12:1971\u20131. https:\/\/doi.org\/10.3390\/diagnostics12081971.","DOI":"10.3390\/diagnostics12081971"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_043","doi-asserted-by":"crossref","unstructured":"D\u2019Agostini, C, Legramante, JM, Minieri, M, Di Lecce, VN, Lia, MS, Maurici, M, et al.. Correlation between chest computed tomography score and laboratory biomarkers in the risk stratification of COVID-19 patients admitted to the emergency department. Diagnostics 2023;13:2829. https:\/\/doi.org\/10.3390\/diagnostics13172829.","DOI":"10.3390\/diagnostics13172829"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_044","doi-asserted-by":"crossref","unstructured":"Alan, M, Grolimund, E, Kutz, A, Christ-Crain, M, Thomann, R, Falconnier, C, et al.. Clinical risk scores and blood biomarkers as predictors of long-term outcome in patients with community-acquired pneumonia: a 6-year prospective follow-up study. J\u00a0Intern Med 2015;278:174\u201384. https:\/\/doi.org\/10.1111\/joim.12341.","DOI":"10.1111\/joim.12341"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_045","doi-asserted-by":"crossref","unstructured":"Uranga, A, Quintana, JM, Aguirre, U, Artaraz, A, Diez, R, Pascual, S, et al.. Predicting 1-year mortality after hospitalization for community-acquired pneumonia. PLoS One 2018;13:e0192750. https:\/\/doi.org\/10.1371\/journal.pone.0192750.","DOI":"10.1371\/journal.pone.0192750"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_046","doi-asserted-by":"crossref","unstructured":"Corrales-Medina, VF, Alvarez, KN, Weissfeld, LA, Angus, DC, Chirinos, JA, Chang, CCH, et al.. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015;313:264. https:\/\/doi.org\/10.1001\/jama.2014.18229.","DOI":"10.1001\/jama.2014.18229"},{"key":"2025121815555026261_j_cclm-2025-0481_ref_047","doi-asserted-by":"crossref","unstructured":"Men\u00e9ndez, R, M\u00e9ndez, R, Ald\u00e1s, I, Reyes, S, Gonzalez-Jimenez, P, Espa\u00f1a, PP, et al.. Community-acquired pneumonia patients at risk for early and long-term cardiovascular events are identified by cardiac biomarkers. Chest 2019;156:1080\u201391. https:\/\/doi.org\/10.1016\/j.chest.2019.06.040.","DOI":"10.1016\/j.chest.2019.06.040"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0481\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0481\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T15:56:34Z","timestamp":1766073394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0481\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2026,1,27]]}},"alternative-id":["10.1515\/cclm-2025-0481"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-0481","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"type":"print","value":"1434-6621"},{"type":"electronic","value":"1437-4331"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}